Drug intelligence / Profile preview

FW-CD

Development stage: Preclinical
Lead developer: Entero Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

FW-CD is a proprietary oral formulation of niclosamide, initially developed by First Wave Bio and subsequently acquired by AzurRx BioPharma, which was later renamed First Wave BioPharma. This drug is specifically being developed for the treatment of Crohn's disease, an inflammatory bowel disease. Its therapeutic action is based on leveraging niclosamide's established anti-inflammatory properties, aiming to address the significant unmet needs within the IBD market.

Beyond the preview

Go deeper on FW-CD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FW-CD.

Explore the full profile